Carien Dekker
Basel, BS 4002, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Discovery and Characterization of Zilurgisertib, a Potent and Selective Inhibitor of Activin Receptor-like Kinase‑2 (ALK2) for the Treatment of Fibrodysplasia Ossificans Progressiva.
Journal: ACS medicinal chemistry letters
Published: August 27, 2025
Correction to "Discovery of DFV890, a Potent Sulfonimidamide-Containing NLRP3 Inflammasome Inhibitor".
Journal: Journal of medicinal chemistry
Published: April 01, 2025
Discovery of DFV890, a Potent Sulfonimidamide-Containing NLRP3 Inflammasome Inhibitor.
Journal: Journal of medicinal chemistry
Published: March 04, 2025
Discovery of NP3-253, a Potent Brain Penetrant Inhibitor of the NLRP3 Inflammasome.
Journal: Journal of medicinal chemistry
Published: November 22, 2024
Discovery of Potent, Orally Bioavailable, Tricyclic NLRP3 Inhibitors.
Journal: Journal of medicinal chemistry
Published: January 04, 2024
A phospho-harmonic orchestra plays the NLRP3 score.
Journal: Frontiers in immunology
Published: August 22, 2023
Crystal Structure of NLRP3 NACHT Domain With an Inhibitor Defines Mechanism of Inflammasome Inhibition.
Journal: Journal of molecular biology
Published: August 13, 2021
Discovery and Structural Characterization of ATP-Site Ligands for the Wild-Type and V617F Mutant JAK2 Pseudokinase Domain.
Journal: ACS chemical biology
Published: February 15, 2019
Lessons from ten years of crystallization experiments at the SGC.
Journal: Acta crystallographica. Section D, Structural biology
Published: September 12, 2015
Using textons to rank crystallization droplets by the likely presence of crystals.
Journal: Acta crystallographica. Section D, Biological crystallography
Published: June 04, 2014
Showing 1-10 of 10
Last Updated: 09/26/2026